Patterns of MRI atrophy in tau positive and ubiquitin positive frontotemporal lobar degeneration.

Memory and Aging Center, and Department of Neurology, University of California, San Francisco, San Francisco, California 94117, USA.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 4.87). 01/2008; 78(12):1375-8. DOI: 10.1136/jnnp.2006.114231
Source: PubMed

ABSTRACT We applied optimised voxel based morphometry (VBM) to brain MRIs from autopsy proven cases of tau positive frontotemporal lobar degeneration (FTLD-T, n = 6), ubiquitin and TDP-43 positive/tau negative FTLD (FTLD-U, n = 8) and cognitively normal controls (n = 61). The analysis revealed that FTLD-T and FTLD-U both show atrophy in the frontal cortex and striatum, but striatal atrophy is more severe in FTLD-T. Manual region of interest tracing of caudate and putamen volumes confirmed the VBM findings. These anatomical differences may help distinguish between FTLD spectrum pathological subtypes in vivo.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease characterized by brain atrophy of the frontal and anterior temporal lobes. The associated frontotemporal dementia syndromes are clinically heterogeneous and the pattern of affected cortical regions varies between subtypes. The TMEM106B rs1990622 polymorphism is associated with FTLD, but little is known about how it affects the brain. Methods We investigated the rs1990622 polymorphism in relation to regional brain volumes to identify potential structures through which TMEM106B confers risk for FTLD. In 4413 non-demented and stroke-free participants from the population-based Rotterdam Study, 150 cortical brain structures and 6 commissural regions were segmented from magnetic resonance imaging (MRI). Results We found a distinct pattern of association between rs1990622 and grey matter volume of left-sided temporal brain regions important for language processing, including the superior temporal gyrus (β = -88.8 μL per risk allele, p = 7.64 x 10-5), which contains Wernicke’s area. The risk allele was also associated with a smaller anterior commissure cross-sectional area (β = -.167 mm2 per risk allele, p = 4.90 x 10-5) and posterior part of the corpus callosum (β = -15.3 μL per risk allele, p = 1.23 X 10-5), both of which contain temporal lobe commissural tracts. Conclusions The asymmetric, predominantly left-sided involvement suggests an effect of TMEM106B on functions lateralized to the dominant hemisphere, such as language. These results show that, in non-demented persons, TMEM106B influences the volume of temporal brain regions which are important for language processing.
    Biological psychiatry 01/2014; · 8.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Frontotemporal dementia (FTD) is an increasingly recognized cause of dementia. This review discusses the different FTD clinical syndromes and frontotemporal lobar degeneration (FTLD) pathological correlates as well as new genetic and proteomic findings that have added to our understanding of FTLD pathogenesis. Various diagnostic modalities including the use of biomarkers will also be addressed. Finally we will highlight future directions in the FTD field. More research is needed to elucidate the cellular mechanisms of neurodegeneration in FTLD and improve clinical diagnostic capabilities.
    International Review of Psychiatry 04/2013; 25(2):210-20. · 1.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Lobar frontotemporal degeneration (FTLD) encompasses a group of molecular disease defined by the deposition of an abnormal protein in the central nervous system. Behavioural variant frontotemporal dementia (bvFTD) is the most frequent clinical presentation of FTLD. The past two decades of research have contributed to a better understanding of this entity, which may be the first manifestation in many different neurodegenerative disorders. DEVELOPMENT: We reviewed correlations between clinical, pathological, and genetic findings and the main disease biomarkers of FTLD, with particular interest in bvFTD. Anatomical pathology findings in FTLD are heterogeneous and the syndrome is not associated with any one specific histopathological type. Promising available biomarkers include structural and functional neuroimaging techniques and biochemical and genetic biomarkers. Disease-modifying drugs designed for specific molecular targets that are implicated in FTLD pathogenesis are being developed. CONCLUSIONS: BvFTD is a frequent cause of dementia. Of all the clinical variants of FTLD, behavioural variant is the one in which establishing a correlation between clinical and pathological signs is the most problematic. A biomarker evaluation may help predict the underlying pathology; this approach, in conjunction with the development of disease-modifying drugs, offers new therapeutic possibilities.
    Neurologia (Barcelona, Spain) 05/2013; · 1.32 Impact Factor


Available from